La pena de muerte en la Corona de Castilla en la Edad Media

[ES]A lo largo de este artículo se pasan revista a cinco cuentiones que muestran la evolución de la pena de muerte en la Corona de Castilla a lo largo de la Edad Media. En primer lugar, se presta atención al paso de la ejecución privada de la justicia a la pública y en qué casos se mantuvo la venganza, aunque con la autorización judicial. En segundo lugar, se pasa revista a las formas de aplicar la pena de muerte, privilegiando los siguientes tipos: el ahorcamiento por los pies, el asaeteamiento, el empozamiento y el encubamiento. En tercer lugar, se expone el ritual de ejecución de las penas capitales desde que el reo sale de la cárcel y es conducido al cadalso, hasta que el cuerpo es sepultado o queda expuesto a perpetuidad. En cuarto lugar, se reflexiona sobre la incidencia de la rebeldía o contumacia del acusado ante los requerimientos de la justicia en la imposición de la pena de muerte. En quinto y último lugar, se analizan las circunstancias que llevaron a la Corona de Castilla, a partir del último tercio del siglo XV, a relegar la pena de muerte entre el elenco punitivo y preferir castigos que tuvieran utilidad pública.

Let sleeping doggerel lie?: James Joyce's "The Death of Parnell" and the challenges of addressing 'bad' verse in translation

Eterio Pajares, Raquel Merino y José Miguel Santamaría (eds.)

1-42 beta-Amyloid peptide requires PDK1/nPKC/Rac 1 pathway to induce neuronal death

1-42 beta-Amyloid (A beta(1-42)) peptide is a key molecule involved in the development of Alzheimer's disease. Some of its effects are manifested at the neuronal morphological level. These morphological changes involve loss of neurites due to cytoskeleton alterations. However, the mechanism of A beta(1-42) peptide activation of the neurodegenerative program is still poorly understood. Here, A beta(1-42) peptide-induced transduction of cellular death signals through the phosphatidylinositol 3-kinase (PI3K)/phosphoinositol- dependent kinase (PDK)/novel protein kinase C (nPKC)/Rac 1 axis is described. Furthermore, pharmacological inhibition of PDK1 and nPKC activities blocks Rac 1 activation and neuronal cell death. Our results provide insights into an unsuspected connection between PDK1, nPKCs and Rac 1 in the same signal-transduction pathway and points out nPKCs and Rac 1 as potential therapeutic targets to block the toxic effects of A beta(1-42) peptide in neurons.

Apaf-1 Inhibitors Protect from Unwanted Cell Death in In Vivo Models of Kidney Ischemia and Chemotherapy Induced Ototoxicity

Background: Excessive apoptosis induces unwanted cell death and promotes pathological conditions. Drug discovery efforts aimed at decreasing apoptotic damage initially targeted the inhibition of effector caspases. Although such inhibitors were effective, safety problems led to slow pharmacological development. Therefore, apoptosis inhibition is still considered an unmet medical need. Methodology and Principal Findings: The interaction between Apaf-1 and the inhibitors was confirmed by NMR. Target specificity was evaluated in cellular models by siRNa based approaches. Cell recovery was confirmed by MTT, clonogenicity and flow cytometry assays. The efficiency of the compounds as antiapoptotic agents was tested in cellular and in vivo models of protection upon cisplatin induced ototoxicity in a zebrafish model and from hypoxia and reperfusion kidney damage in a rat model of hot ischemia. Conclusions: Apaf-1 inhibitors decreased Cytc release and apoptosome-mediated activation of procaspase-9 preventing cell and tissue damage in ex vivo experiments and in vivo animal models of apoptotic damage. Our results provide evidence that Apaf-1 pharmacological inhibition has therapeutic potential for the treatment of apoptosis-related diseases.